{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatocellular+Carcinoma+%28Hepatoma%29&page=27",
    "query": {
      "condition": "Hepatocellular Carcinoma (Hepatoma)",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 1037,
    "total_pages": 104,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatocellular+Carcinoma+%28Hepatoma%29&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatocellular+Carcinoma+%28Hepatoma%29&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T22:18:44.296Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00441376",
      "title": "A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Liver Neoplasms"
      ],
      "interventions": [
        {
          "name": "ThermoDox",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Imunon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2007-02",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2019-02-07",
      "last_synced_at": "2026-10-31T22:18:44.296Z",
      "location_count": 1,
      "location_summary": "Manhasset, New York",
      "locations": [
        {
          "city": "Manhasset",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00441376"
    },
    {
      "nct_id": "NCT01421524",
      "title": "Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Pleiotropic Pathway Modifier",
        "Glioblastoma",
        "Lymphoma",
        "Primary Central Nervous System Lymphoma"
      ],
      "interventions": [
        {
          "name": "CC-122",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 271,
      "start_date": "2011-09-12",
      "completion_date": "2023-11-21",
      "has_results": false,
      "last_update_posted_date": "2023-12-12",
      "last_synced_at": "2026-10-31T22:18:44.296Z",
      "location_count": 17,
      "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01421524"
    },
    {
      "nct_id": "NCT00073736",
      "title": "Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "MB07133 300mg/m2/day",
          "type": "DRUG"
        },
        {
          "name": "MB07133 600 mg/m2/day",
          "type": "DRUG"
        },
        {
          "name": "MB07133 1200 mg/m2/day",
          "type": "DRUG"
        },
        {
          "name": "MB07133 1800 mg/m2/day",
          "type": "DRUG"
        },
        {
          "name": "MB07133 2400 mg/m2/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ligand Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2003-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-08-12",
      "last_synced_at": "2026-10-31T22:18:44.296Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00073736"
    },
    {
      "nct_id": "NCT00087191",
      "title": "EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Advanced Adult Primary Liver Cancer",
        "Carcinoma of the Appendix",
        "Fallopian Tube Cancer",
        "Gastrointestinal Stromal Tumor",
        "Localized Extrahepatic Bile Duct Cancer",
        "Localized Gallbladder Cancer",
        "Localized Gastrointestinal Carcinoid Tumor",
        "Localized Resectable Adult Primary Liver Cancer",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Ovarian Sarcoma",
        "Ovarian Stromal Cancer",
        "Primary Peritoneal Cavity Cancer",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Colon Cancer",
        "Recurrent Extrahepatic Bile Duct Cancer",
        "Recurrent Gallbladder Cancer",
        "Recurrent Gastric Cancer",
        "Recurrent Gastrointestinal Carcinoid Tumor",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Ovarian Germ Cell Tumor",
        "Recurrent Pancreatic Cancer",
        "Recurrent Rectal Cancer",
        "Recurrent Small Intestine Cancer",
        "Recurrent Uterine Sarcoma",
        "Regional Gastrointestinal Carcinoid Tumor",
        "Small Intestine Adenocarcinoma",
        "Small Intestine Leiomyosarcoma",
        "Small Intestine Lymphoma",
        "Stage 0 Non-small Cell Lung Cancer",
        "Stage I Adult Soft Tissue Sarcoma",
        "Stage I Colon Cancer",
        "Stage I Gastric Cancer",
        "Stage I Non-small Cell Lung Cancer",
        "Stage I Ovarian Epithelial Cancer",
        "Stage I Ovarian Germ Cell Tumor",
        "Stage I Pancreatic Cancer",
        "Stage I Rectal Cancer",
        "Stage I Uterine Sarcoma",
        "Stage II Adult Soft Tissue Sarcoma",
        "Stage II Colon Cancer",
        "Stage II Gastric Cancer",
        "Stage II Non-small Cell Lung Cancer",
        "Stage II Ovarian Epithelial Cancer",
        "Stage II Ovarian Germ Cell Tumor",
        "Stage II Pancreatic Cancer",
        "Stage II Rectal Cancer",
        "Stage II Uterine Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma",
        "Stage III Colon Cancer",
        "Stage III Gastric Cancer",
        "Stage III Ovarian Epithelial Cancer",
        "Stage III Ovarian Germ Cell Tumor",
        "Stage III Pancreatic Cancer",
        "Stage III Rectal Cancer",
        "Stage III Uterine Sarcoma",
        "Stage IIIA Non-small Cell Lung Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Adult Soft Tissue Sarcoma",
        "Stage IV Colon Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Ovarian Germ Cell Tumor",
        "Stage IV Pancreatic Cancer",
        "Stage IV Rectal Cancer",
        "Stage IV Uterine Sarcoma",
        "Unresectable Extrahepatic Bile Duct Cancer",
        "Unresectable Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "EF5",
          "type": "DRUG"
        },
        {
          "name": "motexafin lutetium",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-10-31T22:18:44.296Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00087191"
    },
    {
      "nct_id": "NCT04172779",
      "title": "Erlotinib for Hepatocellular Carcinoma Chemoprevention",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cirrhosis, Liver",
        "Advanced Liver Fibrosis"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-12",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-10-31T22:18:44.296Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04172779"
    },
    {
      "nct_id": "NCT01009593",
      "title": "Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma Non-resectable",
        "Hepatocellular Carcinoma Recurrent",
        "Carcinoma, Hepatocellular",
        "Liver Diseases",
        "Neoplasms by Histologic Type",
        "Digestive System Neoplasms",
        "Carcinoma",
        "Liver Neoplasms",
        "Neoplasms",
        "Neoplasms by Site",
        "Digestive System Diseases",
        "Adenocarcinoma",
        "Neoplasms, Glandular and Epithelial"
      ],
      "interventions": [
        {
          "name": "ABT-869",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1035,
      "start_date": "2010-01",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2012-09-10",
      "last_synced_at": "2026-10-31T22:18:44.296Z",
      "location_count": 13,
      "location_summary": "Beverly Hills, California • LaVerne, California • Orange, California + 8 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "LaVerne",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01009593"
    },
    {
      "nct_id": "NCT01639352",
      "title": "Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "SOM230",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Lynn Feun",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2012-07",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2017-07-12",
      "last_synced_at": "2026-10-31T22:18:44.296Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01639352"
    },
    {
      "nct_id": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "NSCLC",
        "Bladder Cancer",
        "HNSCC",
        "Renal Cancer",
        "Melanoma",
        "Anal Cancer",
        "Colorectal Cancer",
        "Cholangiocarcinoma",
        "Gastric Cancer",
        "Hepatocellular Carcinoma",
        "Merkel Cell Carcinoma",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Continue PD-1/PD-L1 Inhibitors treatment",
          "type": "DRUG"
        },
        {
          "name": "Discontinue PD-1/PD-L1-1 inhibitor",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dan Zandberg",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2019-11-15",
      "completion_date": "2025-11-07",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-10-31T22:18:44.296Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04157985"
    },
    {
      "nct_id": "NCT06526338",
      "title": "Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "1.0% IP-001 for injection",
          "type": "DRUG"
        },
        {
          "name": "Surgical Resection and Local Ablation",
          "type": "PROCEDURE"
        },
        {
          "name": "Local Ablation Alone",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Robert C. Martin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 315,
      "start_date": "2024-07-24",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-31T22:18:44.296Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06526338"
    },
    {
      "nct_id": "NCT05757492",
      "title": "Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Non-Small Cell Lung Cancer",
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "CHS-006 (anti-TIGIT)",
          "type": "DRUG"
        },
        {
          "name": "toripalimab (anti-PD-1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Coherus Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2023-04-26",
      "completion_date": "2024-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-01",
      "last_synced_at": "2026-10-31T22:18:44.296Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Detroit, Michigan • Reno, Nevada + 1 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05757492"
    }
  ]
}